🇺🇸 FDA
Pipeline program

Trial of the novel peroral anti-tumor treatment in patients with solid tumors

TU31-KH1

Phase 1 other active

Quick answer

Trial of the novel peroral anti-tumor treatment in patients with solid tumors for Metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed: tumors of lung, head and neck, colon, stomach, esophagus, breast, ovary and/or fallopian tube or primary peritoneal high-grade serous carcinoma is a Phase 1 program (other) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Lacuna Pharma Pty Ltd
Indication
Metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed: tumors of lung, head and neck, colon, stomach, esophagus, breast, ovary and/or fallopian tube or primary peritoneal high-grade serous carcinoma
Phase
Phase 1
Modality
other
Status
active

Clinical trials